19 June 2025 in International Journal of Medical Students
Background: Serum sickness-like reaction (SSLR) is a rare cause of drug eruption. The clinical presentation includes fever, rash, and arthralgia which typically occurs 1-2 weeks after the administration of common antibiotics such as amoxicillin or cefaclor. It is a challenging diagnosis because it mimics sepsis and other exanthematous diseases. Rapid Strep Test (RST) is a useful diagnostic test for detecting Streptococcus pyogenes in patients with pharyngitis and Centor score of 3 or more guiding the administration of antibiotics. The Case: We report a case of a 63-year-old female patient seen in the emergency department (ED) with high-grade fever, diffuse rash, musculoskeletal pain, and a positive RST without clinical evidence of pharyngitis. The primary care physician ordered the RST before the referral to the ED to investigate the febrile rash without a clear indication, misleading to the diagnosis of streptococcal sepsis. She was eventually diagnosed with SSLR and she was treated with corticosteroids, leading to rapid symptomatic relief. Conclusion: SSLR is an interesting clinical entity, and its pathogenesis is poorly understood. This case emphasizes that SSLR is a clinical diagnosis of exclusion after ruling out other similar disorders. Physicians should be familiar with this benign condition to avoid unnecessary diagnostic testing such as RST which may misguide diagnosis and treatment. Simple diagnostic tests should be used with caution under certain indications; misuse of RST can cause false-positive results, complicating the management of these cases.
1 February 2025 in Journal of Medical Cases
Immune checkpoint inhibitors like pembrolizumab represent a modern approach to the management of various malignancies, including non-small cell lung cancer. The therapeutic activity of immunotherapy is exerted by the activation of immune cells against the tumor cells. However, systemic activation of the immune system can lead to the development of autoimmune complications known as immune-related adverse events. A combination of rare immune-related adverse events is occasionally observed simultaneously in the same patient. We present the case of a 66-year-old male with squamous non-small cell lung carcinoma who presented to the emergency department with dyspnea and respiratory failure. Imaging findings were consistent with pulmonary embolism and nonspecific interstitial pneumonitis. One month before this event, he was diagnosed with bullous pemphigoid following 21 cycles of treatment with pembrolizumab. The radiological findings, the lack of response to antibiotics, the negative microbiological workup, and the excellent response to corticosteroids established the diagnosis of pembrolizumab-induced pneumonitis. The combination of bullous pemphigoid and pneumonitis secondary to pembrolizumab is rare; only a few case reports exist in the literature. Hence, this case highlights the possibility of multiple immune-related adverse events in the same patient. The exclusion of infectious diseases and other immunologic disorders with a similar clinical presentation is necessary to make the final diagnosis of immune-related adverse events and start the appropriate treatment. Serology, histopathology, and direct immunofluorescence aid to the diagnosis of immune-related bullous pemphigoid; the differential diagnosis includes other pemphigoid or lichenoid diseases, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. Imaging, microbiological testing, and bronchoscopy (if possible) confirm the diagnosis of immune-related pneumonitis, which should be differentiated from acute coronary syndrome, cardiogenic pulmonary edema, pulmonary embolism, tumor progression, and lower respiratory tract infections (especially Pneumocystis jirovecii pneumonia in immunocompromised patients). An interdisciplinary approach is necessary for the management of these cases.